Takeaway

• In people with type 2 diabetes (T2D) and acute coronary syndrome (ACS), those randomly assigned to ticagrelor had significantly lower rates of major adverse cardiac events (MACE) and mortality.
• Minor bleeding was significantly more common with ticagrelor, but major bleeding was not.

Why this matters

• Guidelines recommend dual antiplatelet...